Raymond James Financial Services Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

Raymond James Financial Services Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-18,600	Closed	-$7K	–	2819
2018 Q2	$7K	Buy	+18,600	New	+$104K	﹤0.01%	2756
2017 Q3	–	Sell	-34,400	Closed	-$3K	–	2566
2017 Q2	$3K	Buy	34,400 +18,400	+115%	+$124K	﹤0.01%	2510
2017 Q1	$10K	Buy	+16,000	New	+$73.9K	﹤0.01%	2413

Other funds holding AUPH

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Raymond James Financial Services Advisors's AUPH Position: Q3 2018 in Review

Raymond James Financial Services Advisors sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2018, closing a stake of 27,200 shares — an estimated $153K sold.

Raymond James Financial Services Advisors first reported a position in AUPH in Q1 2017 and held it in 6 quarters. The position peaked at $260K in Q1 2017. 64 funds tracked by Wall St. Rank hold AUPH as of Q3 2018.

Raymond James Financial Services Advisors reported no remaining Aurinia Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Raymond James Financial Services Advisors sold 27,200 Aurinia Pharmaceuticals shares in Q3 2018, an estimated $153K.
Raymond James Financial Services Advisors first reported a position in Aurinia Pharmaceuticals in Q1 2017 and held it in 6 quarters.
Raymond James Financial Services Advisors's Aurinia Pharmaceuticals position peaked at $260K in Q1 2017.
64 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2018.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.